Abstract:ObjectiveTissue plasminogen activator (tPA) is approved for treatment of acute ischemic stroke, but it increases the risk of cerebral hemorrhage. Accumulating evidence suggests that von Willebrand factor (VWF) plays a pivotal role in thrombus formation and microcirculatory disturbances after ischemic stroke. By cleaving VWF, ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) protects mice from stroke. Therefore, we hypothesized that recombinant ADAMTS13 (rADAMTS13) could increase the safety of tPA thrombolysis in stroke.MethodsWe examined blood–brain barrier (BBB) permeability after intraventricular injection of tPA, VWF, and rADAMTS13 in nonischemic mice. We investigated the role of rADAMTS13 on reducing tPA‐induced BBB dysfunction and cerebral hemorrhage in a mouse stroke model.ResultsIntraventricular injection of tPA or VWF under nonischemic conditions resulted in a significant increase in BBB permeability. In contrast, rADAMTS13 blocked both tPA‐ and VWF‐induced BBB opening. BBB disruption following stroke was exacerbated by intravenous administration of tPA, but this was attenuated by injection of rADAMTS13. Correspondingly, tPA‐associated hemorrhage after stroke was significantly reduced by rADAMTS13. The antihemorrhagic effect of rADAMTS13 was reversed by injection of recombinant VWF. We also showed that rADAMTS13 inhibited tPA‐mediated upregulation of vascular endothelial growth factor (VEGF) in vascular endothelium after stroke. The upregulation of VEGF was suppressed by either an Akt inhibitor wortmannin or a Rho kinase inhibitor fasudil. Furthermore, rADAMTS13 downregulated tPA‐induced phosphorylation of Akt and activation of RhoA.InterpretationThese findings demonstrate that the VWF‐cleaving protease rADAMTS13 reduced tPA‐induced hemorrhage by regulating BBB integrity, and suggest that this effect may occur through the Akt/RhoA‐mediated VEGF pathways. ANN NEUROL 2013;73:189–198

Influence of Thrombolysis on the Safety and Efficacy of Blocking Platelet Adhesion or Secretory Activity in Acute Ischemic Stroke in Mice

A Rat Model of Studying Tissue-Type Plasminogen Activator Thrombolysis in Ischemic Stroke with Diabetes

Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion

Platelets and lymphocytes drive progressive penumbral tissue loss during middle cerebral artery occlusion in mice

Neutrophil migration participates in the side effect of recombinant human tissue plasminogen activator

Single- and two- chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke

Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment

Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke

Cold Case of Thrombolysis: Cold Recombinant Tissue Plasminogen Activator Confers Enhanced Neuroprotection in Experimental Stroke

Platelet glycoprotein receptor Ib blockade ameliorates experimental cerebral ischemia-reperfusion injury by strengthening the blood-brain barrier function and anti-thrombo-inflammatory property

Improving Stroke Outcomes in Hyperglycemic Mice by Modulating tPA/NMDAR Signaling to Reduce Inflammation and Hemorrhages

Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance.

Pretreatment with a dual antiplatelet and anticoagulant (APAC) reduces ischemia–reperfusion injury in a mouse model of temporary middle cerebral artery occlusion—implications for neurovascular procedures

Neutrophil extracellular traps contribute to tissue plasminogen activator resistance in acute ischemic stroke

Recombinant ADAMTS13 Reduces Tissue Plasminogen Activator‐induced Hemorrhage after Stroke in Mice

Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment

Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'

Pharmacological inhibition of phospholipase D protects mice from occlusive thrombus formation and ischemic stroke--brief report

New mechanisms-based therapies in acute ischaemic stroke

Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant Adamts 13

Annexin V‐modified platelet‐biomimetic nanomedicine for targeted therapy of acute ischemic stroke